Brentuximab vedotin, an antibody-drug conjugate targeting the CD30 molecule, and anti-PD-1 monoclonal antibodies (nivolumab and pembrolizumab) have changed the landscape of r/r cHL following ASCT with high clinical response rates while maintaining a relatively tolerable side effect profile. This evidence concerns the gene PDCD1 and classic Hodgkin lymphoma.